Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 134

1.

Immune response to vaccine adjuvants during the first year of life.

Levy O, Goriely S, Kollmann TR.

Vaccine. 2013 May 17;31(21):2500-5. doi: 10.1016/j.vaccine.2012.10.016. Epub 2012 Oct 18. Review.

2.

Aluminium-adjuvanted vaccines--a review of the current state of knowledge.

Gołoś A, Lutyńska A.

Przegl Epidemiol. 2015;69(4):731-4, 871-4. Review. English, Polish.

3.

Adjuvant-induced Human Monocyte Secretome Profiles Reveal Adjuvant- and Age-specific Protein Signatures.

Oh DY, Dowling DJ, Ahmed S, Choi H, Brightman S, Bergelson I, Berger ST, Sauld JF, Pettengill M, Kho AT, Pollack HJ, Steen H, Levy O.

Mol Cell Proteomics. 2016 Jun;15(6):1877-94. doi: 10.1074/mcp.M115.055541. Epub 2016 Mar 1.

4.

Comparison of the reactogenicity and immunogenicity of a split and a subunit-adjuvanted influenza vaccine in elderly subjects.

Squarcione S, Sgricia S, Biasio LR, Perinetti E.

Vaccine. 2003 Mar 7;21(11-12):1268-74.

PMID:
12559808
5.

Adjuvants for veterinary vaccines--types and modes of action.

Gerdts V.

Berl Munch Tierarztl Wochenschr. 2015 Nov-Dec;128(11-12):456-63. Review.

PMID:
26697712
6.

Immunopathology of RSV infection: prospects for developing vaccines without this complication.

van Drunen Littel-van den Hurk S, Mapletoft JW, Arsic N, Kovacs-Nolan J.

Rev Med Virol. 2007 Jan-Feb;17(1):5-34. Review.

PMID:
17004293
7.

Novel Adjuvants and Immunomodulators for Veterinary Vaccines.

Heegaard PM, Fang Y, Jungersen G.

Methods Mol Biol. 2016;1349:63-82. doi: 10.1007/978-1-4939-3008-1_5.

PMID:
26458830
8.

Priming with AS03 A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: an open non-randomised extension of a double-blind randomised primary study.

Leroux-Roels I, Roman F, Forgus S, Maes C, De Boever F, Dramé M, Gillard P, van der Most R, Van Mechelen M, Hanon E, Leroux-Roels G.

Vaccine. 2010 Jan 8;28(3):849-57. doi: 10.1016/j.vaccine.2009.10.017. Epub 2009 Oct 14.

PMID:
19835828
9.

Vaccine adjuvants: putting innate immunity to work.

Coffman RL, Sher A, Seder RA.

Immunity. 2010 Oct 29;33(4):492-503. doi: 10.1016/j.immuni.2010.10.002. Review.

10.

The search for novel adjuvants for early life vaccinations: can "danger" motifs show us the way?

Kovarik J, Siegrist CA.

Arch Immunol Ther Exp (Warsz). 2001;49(3):209-15. Review.

PMID:
11478395
11.

Vaccine adjuvants: role and mechanisms of action in vaccine immunogenicity.

Marciani DJ.

Drug Discov Today. 2003 Oct 15;8(20):934-43. Review.

PMID:
14554157
12.

Vaccine adjuvant systems: enhancing the efficacy of sub-unit protein antigens.

Perrie Y, Mohammed AR, Kirby DJ, McNeil SE, Bramwell VW.

Int J Pharm. 2008 Dec 8;364(2):272-80. doi: 10.1016/j.ijpharm.2008.04.036. Epub 2008 Apr 30. Review.

PMID:
18555624
13.

Targeting the innate immune response with improved vaccine adjuvants.

Pashine A, Valiante NM, Ulmer JB.

Nat Med. 2005 Apr;11(4 Suppl):S63-8. Review.

PMID:
15812492
14.

The global impact of vaccines containing aluminium adjuvants.

Clements CJ, Griffiths E.

Vaccine. 2002 May 31;20 Suppl 3:S24-33. Review.

PMID:
12184361
15.

Immunopotentiation of Different Adjuvants on Humoral and Cellular Immune Responses Induced by HA1-2 Subunit Vaccines of H7N9 Influenza in Mice.

Song L, Xiong D, Hu M, Kang X, Pan Z, Jiao X.

PLoS One. 2016 Mar 1;11(3):e0150678. doi: 10.1371/journal.pone.0150678. eCollection 2016.

16.

Enhancement of vaccine potency through improved delivery.

Ulmer JB.

Expert Opin Biol Ther. 2004 Jul;4(7):1045-51. Review.

PMID:
15268672
17.

Vaccine adjuvants: current challenges and future approaches.

Wilson-Welder JH, Torres MP, Kipper MJ, Mallapragada SK, Wannemuehler MJ, Narasimhan B.

J Pharm Sci. 2009 Apr;98(4):1278-316. doi: 10.1002/jps.21523. Review.

PMID:
18704954
18.

Unmet needs in modern vaccinology: adjuvants to improve the immune response.

Leroux-Roels G.

Vaccine. 2010 Aug 31;28 Suppl 3:C25-36. doi: 10.1016/j.vaccine.2010.07.021. Review.

PMID:
20713254
19.

MF59-adjuvanted vaccines: increased immunogenicity with an optimal safety profile.

Podda A, Del Giudice G.

Expert Rev Vaccines. 2003 Apr;2(2):197-203. Review.

PMID:
12899571
20.

Adjuvants for human vaccines--current status, problems and future prospects.

Gupta RK, Siber GR.

Vaccine. 1995 Oct;13(14):1263-76. Review.

PMID:
8585280

Supplemental Content

Support Center